Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 11.40 +0.15 (+1.33%)
As of 09/3/2026 11:25 AM Eastern
Compare

CRTX vs. EMH, GDP, BZT, ZIOC, and KAV

Should you buy CRISM Therapeutics stock or one of its competitors? CRISM Therapeutics's main competitors and comparable companies include European Metals (EMH), Goldplat (GDP), Bezant Resources (BZT), Zanaga Iron Ore (ZIOC), and Kavango Resources (KAV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "metals & mining" industry.

How does CRISM Therapeutics compare to European Metals?

CRISM Therapeutics (LON:CRTX) and European Metals (LON:EMH) are both small-cap materials companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

0.3% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 1.9% of European Metals shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 1.2% of European Metals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled European Metals'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
European Metals Neutral

CRISM Therapeutics has a net margin of 0.00% compared to European Metals' net margin of -287.87%. European Metals' return on equity of -25.49% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
European Metals -287.87%-25.49%-2.47%

CRISM Therapeutics has a beta of 0.565, suggesting that its share price is 44% less volatile than the broader market. Comparatively, European Metals has a beta of 0.291, suggesting that its share price is 71% less volatile than the broader market.

CRISM Therapeutics has higher revenue and earnings than European Metals. European Metals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A
European MetalsN/AN/A-£2.30M-£3.81N/A

Summary

CRISM Therapeutics beats European Metals on 6 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Goldplat?

Goldplat (LON:GDP) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, Goldplat's average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Goldplat Neutral
CRISM Therapeutics Neutral

Goldplat has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Goldplat, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Goldplat£72.22M0.43N/A£1.6810.86
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A

1.8% of Goldplat shares are held by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are held by institutional investors. 39.9% of Goldplat shares are held by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Goldplat has a net margin of 3.99% compared to CRISM Therapeutics' net margin of 0.00%. Goldplat's return on equity of 11.74% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Goldplat3.99% 11.74% 5.78%
CRISM Therapeutics N/A -139.63%-26.77%

Goldplat has a beta of 0.091, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.565, suggesting that its stock price is 44% less volatile than the broader market.

Summary

Goldplat beats CRISM Therapeutics on 7 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Bezant Resources?

Bezant Resources (LON:BZT) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Bezant Resources' return on equity of 21.18% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bezant ResourcesN/A 21.18% -41.17%
CRISM Therapeutics N/A -139.63%-26.77%

1.5% of Bezant Resources shares are held by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are held by institutional investors. 7.3% of Bezant Resources shares are held by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Bezant Resources had 2 more articles in the media than CRISM Therapeutics. MarketBeat recorded 2 mentions for Bezant Resources and 0 mentions for CRISM Therapeutics. Bezant Resources' average media sentiment score of 0.43 beat CRISM Therapeutics' score of 0.00 indicating that Bezant Resources is being referred to more favorably in the media.

Company Overall Sentiment
Bezant Resources Neutral
CRISM Therapeutics Neutral

Bezant Resources has higher earnings, but lower revenue than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Bezant Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bezant ResourcesN/AN/A-£8.40K£0.0117.19
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A

Bezant Resources has a beta of 0.852, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.565, suggesting that its stock price is 44% less volatile than the broader market.

Summary

Bezant Resources beats CRISM Therapeutics on 8 of the 11 factors compared between the two stocks.

How does CRISM Therapeutics compare to Zanaga Iron Ore?

CRISM Therapeutics (LON:CRTX) and Zanaga Iron Ore (LON:ZIOC) are both small-cap materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Zanaga Iron Ore has lower revenue, but higher earnings than CRISM Therapeutics. Zanaga Iron Ore is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A
Zanaga Iron OreN/AN/A-£4.62K-£0.90N/A

CRISM Therapeutics has a beta of 0.565, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Zanaga Iron Ore has a beta of 1.888, suggesting that its stock price is 89% more volatile than the broader market.

Zanaga Iron Ore's return on equity of -4.06% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Zanaga Iron Ore N/A -4.06%-2.48%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Zanaga Iron Ore'saverage media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Zanaga Iron Ore Neutral

0.3% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 2.2% of Zanaga Iron Ore shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by insiders. Comparatively, 12.9% of Zanaga Iron Ore shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Zanaga Iron Ore beats CRISM Therapeutics on 6 of the 9 factors compared between the two stocks.

How does CRISM Therapeutics compare to Kavango Resources?

Kavango Resources (LON:KAV) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Kavango Resources has a beta of 0.274, indicating that its stock price is 73% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.565, indicating that its stock price is 44% less volatile than the broader market.

In the previous week, Kavango Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Kavango Resources Neutral
CRISM Therapeutics Neutral

CRISM Therapeutics has a net margin of 0.00% compared to Kavango Resources' net margin of -869.55%. Kavango Resources' return on equity of -68.85% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kavango Resources-869.55% -68.85% -14.06%
CRISM Therapeutics N/A -139.63%-26.77%

0.3% of CRISM Therapeutics shares are held by institutional investors. 8.7% of Kavango Resources shares are held by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kavango Resources has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Kavango Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kavango Resources£1.72M15.85-£5.48K-£0.48N/A
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A

Summary

Kavango Resources beats CRISM Therapeutics on 6 of the 11 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsMetals & Mining IndustryMaterials SectorLON Exchange
Market Cap£9.03M£4.05B£5.07B£2.91B
Dividend YieldN/A5.17%4.67%6.18%
P/E Ratio-2.2425.5826.18364.48
Price / Sales39.088,871.175,280.5083,785.86
Price / CashN/A29.6827.0927.89
Price / Book0.2612.7410.636.81
Net Income-£792.20K£125.14M£156.32M£5.89B
7 Day PerformanceN/A-0.24%-0.28%-0.84%
1 Month Performance26.67%21.37%16.21%2.08%
1 Year Performance12.54%57.36%45.06%21.69%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 11.40
+1.3%		N/A+12.5%£9.03M£231KN/A4
EMH
European Metals
N/AGBX 14
+3.7%		N/A+51.5%£33.26MN/AN/AN/A
GDP
Goldplat
N/AGBX 18.45
-1.6%		N/A+122.6%£31.51M£72.22M10.98458
BZT
Bezant Resources
N/AGBX 0.14
flat		N/A+212.2%£31.27MN/A15.735
ZIOC
Zanaga Iron Ore
N/AGBX 3.15
-8.3%		N/A-55.7%£31.25MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel